Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! By
Prevalence and Clinicopathologic Features of Her2 Overexpression in Endocervical Adenocarcinoma Publisher



N Momeni NIUSHA ; F Nili FATEMEH ; F Ameli FERESHTEH ; S Sarmadi SOHEILA ; E Mirzaian ELHAM ; F Moravejsalehi FARNAZ ; N Zamani NARGES
Authors

Source: Middle East Journal of Cancer Published:2025


Abstract

Background: Endocervical adenocarcinoma (ENCA) has poor prognosis and is increasing in developing countries. Human epidermal growth factor receptor 2 (HER2) overexpression in ENCA is not fully known. The aim of this study was to assess the prevalence and clinicopathological features of HER2 overexpression in ENCA. Method: In this cohort study, 48 ENCA cases were reclassified using the World Health Organization (WHO) classification. Whole-tissue sections were stained for HER2 by immunohistochemistry (IHC) and scored using 2017 American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) protocol (negative=0, 1+, equivocal=2+, and positive=3+). Fluorescent in situ hybridization (FISH) assay was performed for 2+ stained cases. Invasion growth pattern and clinicopathologic features were investigated. Statistical analysis was performed using Statistical Package for Social Sciences (SPSS) and Statistical software for data science (STATA) with chi square, Fischer exact, independent sample t-test, and one-way Analysis of Variance (ANOVA) at 0.05 significance level. Results: 16.6% of ENCAs overexpressed HER2, IHC3+ (n=6) and IHC2+ (n=2). No human papilloma virus (HPV)-independent case was found. HER2 was expressed in half of the invasive stratified mucin-producing carcinomas (ISMICs) (P < 0.05) and was not associated with stage, metastasis, lymph-vascular space invasion, lymph node metastasis, or pattern of invasion (P > 0.05). Conclusion: ENCAs, including HPV-associated subtypes, overexpress HER2 in about 16.6% of the cases. Overexpression in ISMIC is significantly higher than the other subtypes, which can be considered for therapeutic trials in this histopathologic subcategory. © 2025 Elsevier B.V., All rights reserved.
Related Docs
View other Related Docs
1. Her2 Overexpression in Borderline and Malignant Ovarian Tumors: A Cross-Sectional Study in an Iranian Population and Literature Review, Middle East Journal of Cancer (2018)
2. Her-2 Overexpression in Female Genital Tract Clear Cell Carcinomas: Evaluation of Different Scoring Guidelines, Clinicopathological Features and Prognostic Impact, Annals of Diagnostic Pathology (2023)
3. Her2 Gene Amplification in Patients With Prostate Cancer: Evaluating a Cish-Based Method, Oncology Letters (2016)
Experts (# of related papers)
View all Related Experts
Fatemeh Nili Ahmadabadi (2)
Ramesh Omranipoor (2)
Other Related Docs
4. Radiolabeled Her2-Targeted Molecular Probes in Breast Cancer Imaging: Current Knowledge and Future Prospective, Naunyn-Schmiedeberg's Archives of Pharmacology (2025)
5. Evaluation of Her2 Positivity Based on Clinicopathological Findings in Her2 Borderline Tumors in Iranian Patients With Breast Cancer, Iranian Journal of Pathology (2023)
6. Evaluation of Her2 Gene Amplification Using Cish in Patients With Her2 2+ (Equivocal) Breast Carcinoma Based on Immunohistochemistry, Archives of Breast Cancer (2023)
7. The Survey of Her2/Neu Expression and It’S Correlation With Some Pathological Factors in Urothelial Bladder Tumors, Iranian Red Crescent Medical Journal (2018)
8. Epitope Mapping of Human Her2 Specific Mouse Monoclonal Antibodies Using Recombinant Extracellular Subdomains, Asian Pacific Journal of Cancer Prevention (2017)
9. Evaluation of the Her-2/Neu Value in Papillary Thyroid Carcinoma and Its Relation to Histopathological Prognostic Findings, Cancer Treatment and Research Communications (2024)
10. Imaging Features of Estrogen-Negative Breast Cancers: A Correlation Study With Human Epidermal Growth Factor Type Ii Overexpression, Tehran University Medical Journal (2018)
11. The Value of Epidermal Growth Factor Receptor Expression in Predicting Aggressive Behaviors of Bladder Neoplasms, Nephro-Urology Monthly (2023)
12. Polyclonal Antibody Against Different Extracellular Subdomains of Her2 Induces Tumor Growth Inhibition in Vitro, Iranian Journal of Immunology (2017)
13. Pathological Characteristics of Triple-Negative Breast Cancer at Main Referral Teaching Hospital, April 2014 to April 2015, Tehran, Iran, International Journal of Hematology-Oncology and Stem Cell Research (2016)
14. The Core Needle and Surgical Biopsy Concordance to Detect Estrogen, Progesterone, and Her-2 Receptors in Breast Cancer: A Comparative Study, Iranian Journal of Pathology (2017)
15. The Role of Her2 Alterations in Clinicopathological and Molecular Characteristics of Breast Cancer and Her2-Targeted Therapies: A Comprehensive Review, Medical Oncology (2022)
16. Production of Human Single-Chain Fragment Antibody (Scfv) Against Human Epidermal Growth Factor Receptor-2 (Her-2) by Phage Display Technology, In Vitro Cellular and Developmental Biology - Animal (2018)
17. Human Epidermal Growth Factor Receptor 2 [Her-2/Neu] Amplification and Microsatellite Stable Status in Gastric and Gastroesophageal Adenocarcinoma: Assessing Frequency and Prognostic Implications at the Cancer Institute of Iran, Cancer Reports (2025)
18. Chromogenic in Situ Hybridisation Test for Breast Cancer Patients With Equivocal Ihc Results - a Study From Iran, Asian Pacific Journal of Cancer Prevention (2015)
19. Sonographic Features of Estrogen-Negative Breast Cancers: A Correlation Study With Human Epidermal Growth Factor Type Ii Overexpression, Journal of Diagnostic Medical Sonography (2018)
20. A Meta-Analysis on Concordance Between Immunohistochemistry (Ihc) and Fluorescence in Situ Hybridization (Fish) to Detect Her2 Gene Overexpression in Breast Cancer, Breast Cancer (2015)